Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

Benzinga10-17

On Thursday, Amicus Therapeutics (NASDAQ:FOLD) announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. (NYSE:TEVA). The agreement resolves the patent litigation brought ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476170144?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dWYBVF1P7Itw9dFfx6T29w--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/fda56ac5d68329a835953222895e11df","is_english":true,"pubTime":"2024-10-17 23:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2476170144","market":"us","top_or_hot":-1,"title":"Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug","media":"Benzinga","content":"<div>\n<p>On Thursday, Amicus Therapeutics (NASDAQ:FOLD) announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. (NYSE:TEVA).\nThe agreement resolves the patent litigation brought ...</p>\n\n<a href=\"https://finance.yahoo.com/news/amicus-therapeutics-settles-patent-lawsuit-150741097.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/amicus-therapeutics-settles-patent-lawsuit-150741097.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Thursday, Amicus Therapeutics (NASDAQ:FOLD) announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. (NYSE:TEVA).\nThe agreement resolves the patent litigation brought ...</p>\n\n<a href=\"https://finance.yahoo.com/news/amicus-therapeutics-settles-patent-lawsuit-150741097.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://finance.yahoo.com/news/amicus-therapeutics-settles-patent-lawsuit-150741097.html","article_id":"2476170144","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dWYBVF1P7Itw9dFfx6T29w--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/fda56ac5d68329a835953222895e11df"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476170144","pubTimestamp":1729177661,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Thursday, Amicus Therapeutics announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. .The agreement resolves the patent litigation brought by Amicus in response to Teva’s Abbreviated New Drug Application  seeking approval to market a generic version of Galafold  123mg capsules before the expiration of the applicable patents.Also Read: Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes.Under the terms of the Agreement, Amicus will grant Teva a license to market its generic version of Galafoldin theUnited Statesbeginning on January 30, 2037, if approved by the FDA and unless certain limited circumstances customarily included in these types of agreements occur.The parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Teva regarding Galafold patents pending in the U.S. District Court for the District of Delaware.The litigation will continue against Aurobindoas the remaining active party, and the litigation stay remain","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK4559":"巴菲特持仓","FOLD":"爱美医疗","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","GENE":"基因技术ADR","BK4588":"碎股","BK4007":"制药","TEVA":"梯瓦制药","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4584":"避孕概念","BK4566":"资本集团","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4557":"大麻股"},"translate_title":"Amicus Therapeutics就其罕见遗传疾病药物仿制药与梯瓦制药(Teva Pharmaceuticals)的专利诉讼达成和解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FOLD":1,"GENE":1,"TEVA":1},"content_text":"On Thursday, Amicus Therapeutics (NASDAQ:FOLD) announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. (NYSE:TEVA).\nThe agreement resolves the patent litigation brought by Amicus in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Galafold (migalastat) 123mg capsules before the expiration of the applicable patents.\nAlso Read: Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes.\nGalafold is a medication for Fabry disease, a rare genetic disorder caused by the buildup of a type of fat called globotriaosylceramide in the body’s cells.\nUnder the terms of the Agreement, Amicus will grant Teva a license to market its generic version of Galafold in the United States beginning on January 30, 2037, if approved by the FDA and unless certain limited circumstances customarily included in these types of agreements occur.\nThe parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Teva regarding Galafold patents pending in the U.S. District Court for the District of Delaware.\nThe litigation will continue against Aurobindo as the remaining active party, and the litigation stay remains in place for Lupin.\nPrice Action: TEVA stock is up 0.47% at $18.11, and FOLD stock is up 12.4% at $11.81 at last check Thursday.\nImage via Unsplash\nRead Next:\n\nCommercial Metals Q4 EPS Beats By A Whisker, But Outlook Signals Tough Start To 2025.\n\nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nTEVA PHARMACEUTICAL INDUS (TEVA): Free Stock Analysis Report\nAMICUS THERAPEUTICS (FOLD): Free Stock Analysis Report\n\nThis article Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476170144"}